{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T21:54:14Z","timestamp":1770501254357,"version":"3.49.0"},"reference-count":36,"publisher":"Wiley","issue":"s2","license":[{"start":{"date-parts":[[2014,3,31]],"date-time":"2014-03-31T00:00:00Z","timestamp":1396224000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"LEO Pharma"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2014,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The fixed combination calcipotriol plus betamethasone dipropionate gel is a first\u2010line treatment for psoriasis vulgaris. The objective was to perform a large\u2010scale assessment of tolerability of fixed combination gel (Cal\/<jats:styled-content style=\"fixed-case\">BD<\/jats:styled-content>). Analysis was performed on pooled 8\u2010week safety data from nine clinical trials evaluating once\u2010daily Cal\/<jats:styled-content style=\"fixed-case\">BD<\/jats:styled-content> treatment of scalp (<jats:italic>n\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>6) and body (<jats:italic>n\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>3) psoriasis. Pharmacovigilance data were also assessed. Patients were treated with Cal\/<jats:styled-content style=\"fixed-case\">BD<\/jats:styled-content> [<jats:italic>n\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>1953 (scalp), <jats:italic>n\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>824 (body)], betamethasone dipropionate gel (<jats:styled-content style=\"fixed-case\">BD<\/jats:styled-content>;<jats:italic> n\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>1214, <jats:italic>n\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>562), calcipotriol gel (Cal; <jats:italic>n\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>979, <jats:italic>n\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>175), gel vehicle (<jats:styled-content style=\"fixed-case\">VEH<\/jats:styled-content>;<jats:italic> n\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>173, <jats:italic>n\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>226), calcipotriol scalp solution [<jats:italic>n\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>104 (scalp only)] and tacalcitol ointment [<jats:styled-content style=\"fixed-case\">TAC<\/jats:styled-content>;<jats:italic> n\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>184 (body only)]. Most adverse events (<jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>s) were mild\u2013moderate severity. The proportion of scalp psoriasis patients with \u22651 <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content> was lowest with Cal\/<jats:styled-content style=\"fixed-case\">BD<\/jats:styled-content> (35% versus 38\u201357%). A similar proportion was found with Cal\/<jats:styled-content style=\"fixed-case\">BD<\/jats:styled-content> for body psoriasis (32%), however, lower proportions were reported with <jats:styled-content style=\"fixed-case\">BD<\/jats:styled-content> (24%) and Cal (29%). The most common <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>s with Cal\/<jats:styled-content style=\"fixed-case\">BD<\/jats:styled-content> included nasopharyngitis, pruritus and upper respiratory tract infection (2\u20135% of patients). Overall, only 5% of patients treated with Cal\/<jats:styled-content style=\"fixed-case\">BD<\/jats:styled-content> reported \u22651 lesional\/perilesional <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>s: the lowest incidence versus scalp comparators (6\u201319%) and second lowest to <jats:styled-content style=\"fixed-case\">BD<\/jats:styled-content> (3%) for body psoriasis. Similarly, Cal\/<jats:styled-content style=\"fixed-case\">BD<\/jats:styled-content> treatment resulted in the lowest incidence of \u22651 adverse drug reactions (<jats:styled-content style=\"fixed-case\">ADR<\/jats:styled-content>s) in scalp psoriasis patients (8% versus 9\u201327%) and second lowest to <jats:styled-content style=\"fixed-case\">BD<\/jats:styled-content> (6% versus 4%) for body psoriasis. Overall, incidence of serious <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>s (<jats:styled-content style=\"fixed-case\">SAE<\/jats:styled-content>s) was low (0\u20131%). Data received postmarketing through spontaneous reporting revealed that <jats:styled-content style=\"fixed-case\">SAE<\/jats:styled-content>s reported more than once with Cal\/<jats:styled-content style=\"fixed-case\">BD<\/jats:styled-content> treatment were psoriasis (<jats:italic>n\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>5); and alopecia, erythrodermic psoriasis, pruritus, skin atrophy and urticaria (<jats:italic>n\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>2 each). In this large subset of patients treated with Cal\/<jats:styled-content style=\"fixed-case\">BD<\/jats:styled-content>, incidence of <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>s and <jats:styled-content style=\"fixed-case\">ADR<\/jats:styled-content>s is consistently low. This analysis provides further evidence of the good tolerability of the fixed combination gel as treatment for psoriasis vulgaris.<\/jats:p>","DOI":"10.1111\/jdv.12444","type":"journal-article","created":{"date-parts":[[2014,3,31]],"date-time":"2014-03-31T07:41:02Z","timestamp":1396251662000},"page":"10-21","source":"Crossref","is-referenced-by-count":20,"title":["Pooled safety analysis of calcipotriol plus betamethasone dipropionate gel for the treatment of psoriasis on the body and scalp"],"prefix":"10.1111","volume":"28","author":[{"given":"K.","family":"Kragballe","sequence":"first","affiliation":[{"name":"Department of Dermatology \u00c5rhus University Hospital \u00c5rhus Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"van de Kerkhof","sequence":"additional","affiliation":[{"name":"Department of Dermatology Radboud University Medical Centre Nijmegen The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,3,31]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2007.02424.x"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199503023320907"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61128-3"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-4-35"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8019.2010.01312.x"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)70112-X"},{"key":"e_1_2_6_8_1","first-page":"878","article-title":"Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step\u2010down dose in patients with moderate\u2010to\u2010severe plaque psoriasis: results of an open label trial","volume":"10","author":"Kircik LH","year":"2011","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.030791"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.12.032"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-012-1214-8"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e6712"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.09791.x"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2011.565017"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/00015550252948194"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.2165\/11207300-000000000-00000"},{"key":"e_1_2_6_17_1","first-page":"92","article-title":"Calcipotriene plus betamethasone dipropionate topical suspension for the treatment of mild to moderate psoriasis vulgaris on the body: a randomized, double\u2010blind, vehicle\u2010controlled trial","volume":"12","author":"Menter A","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_18_1","first-page":"1","article-title":"Treatments for scalp psoriasis with emphasis on calcipotriol plus betamethasone dipropionate gel (Xamiol\u00ae)","volume":"14","author":"Guenther LC","year":"2009","journal-title":"Skin Therapy Lett"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1159\/000323408"},{"key":"e_1_2_6_20_1","first-page":"e129","article-title":"The biological rationale for use of vitamin D analogs in combination with corticosteroids for the topical treatment of plaque psoriasis","volume":"12","author":"Segaert S","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04060.x"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04525.x"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08927.x"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1159\/000130425"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.04.027"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09116.x"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1159\/000155642"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2010.04598.x"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2010.0948"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0733-8635(18)30290-0"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200102020-00008"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200506060-00005"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-7-62"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1159\/000329026"},{"key":"e_1_2_6_35_1","first-page":"32","article-title":"The roles of safety and compliance in determining effectiveness of topical therapy for psoriasis","volume":"79","author":"Stein Gold L","year":"2007","journal-title":"Cutis"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200203030-00001"},{"key":"e_1_2_6_37_1","first-page":"882","article-title":"Effect of calcipotriene plus betamethasone dipropionate topical suspension on the hypothalamic\u2010pituitary\u2010adrenal axis and calcium homeostasis in subjects with extensive psoriasis vulgaris: an open, non\u2010controlled, 8\u2010week trial","volume":"12","author":"Silver S","year":"2013","journal-title":"J Drugs Dermatol"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.12444","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.12444","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.12444","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T03:58:33Z","timestamp":1694491113000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.12444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,31]]},"references-count":36,"journal-issue":{"issue":"s2","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["10.1111\/jdv.12444"],"URL":"https:\/\/doi.org\/10.1111\/jdv.12444","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,31]]}}}